Non-small cell lung cancer · line 2 · Amivantamab + Lazertinib (MARIPOSA-2) — 2L EGFR-mut NSCLC post-osimertinib

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	2
Track	aggressive
Linked regimen	`REG-AMIVANTAMAB-LAZERTINIB-NSCLC-2L`

ID	`IND-NSCLC-2L-EGFR-POST-OSI-AMI-LAZ`
Type	Indication
Status	reviewed 2026-04-27 \| pending_clinical_signoff
Diseases	`DIS-NSCLC`
Sources	`SRC-ESMO-NSCLC-METASTATIC-2024` `SRC-MARIPOSA2-PASSARO-2024` `SRC-NCCN-NSCLC-2025`

Notes

STUB — pending Clinical Co-Lead sign-off. Aggressive-track 2L for EGFR-mutated NSCLC post-osimertinib failure. Reuses REG-AMIVANTAMAB-LAZERTINIB-NSCLC-2L. PAPILLON (1L Ex20ins) and MARIPOSA (1L EGFR-mut) are separate Indications. Resistance mutation profile (T790M, C797S, MET-amp, HER2-mut) drives precise 3L+ sequencing — separate future Indications.

Used By

Algorithms

ALGO-NSCLC-METASTATIC-2L - ALGO-NSCLC-METASTATIC-2L

Indication

IND-NSCLC-2L-MET-AMP-CAPMATINIB - IND-NSCLC-2L-MET-AMP-CAPMATINIB
IND-NSCLC-EGFR-1L-AMI-LAZ - IND-NSCLC-EGFR-1L-AMI-LAZ
IND-NSCLC-EGFR-1L-OSI-CHEMO - IND-NSCLC-EGFR-1L-OSI-CHEMO